Skip to main content

Advertisement

SpringerLink
Log in

Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Clinical pharmacy can reduce drug-related iatrogenesis by improving the management of adverse effects of drugs, limiting drug–drug interactions, and improving patient adherence. Given the vulnerability of cancer patients and the toxicity of injectable anticancer drugs, clinical pharmacy service (CPS) could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on clinical pharmacy’s impact on patients treated with intravenous anticancer drugs.

Methods

A comprehensive search was performed in the PubMed/Medline database from January 2000 to December 2021, associating the keywords: clinical pharmacy, pharmaceutical care, pharmacist, oncology, and chemotherapy. To be eligible for inclusion, studies have to report clinical pharmaceutical services for patients treated with intravenous chemotherapy with a clinical and/or economic impact.

Results

Forty-one studies met the selection criteria. Various CPS were reported: medication reconciliation, medication review, and pharmaceutical interview with patient. There was a lack of randomized study (n = 3; 7.3%). In one randomized controlled trial, pharmaceutical intervention significantly improved quality of life of patients receiving pharmaceutical care during injectable anticancer drugs courses. Economical results appear to show positive impact of clinical pharmacy with cost savings reported from 3112.87$ to 249 844€. Although most studies were non-comparative, they highlighted that clinical pharmacy tend to limit chemotherapy side effects and drug-related problems, improve quality of life and satisfaction of patients and healthcare professional, and a positive economic impact.

Conclusion

Clinical pharmacy can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Ahmed A, Saqlain M, Tanveer M, Blebil AQ, Dujaili JA, Hasan SS (2021) The impact of clinical pharmacist services on patient health outcomes in Pakistan: a systematic review. BMC Health Serv Res 21:859

    PubMed  PubMed Central  Google Scholar 

  • Ali K, Al-Quteimat O, Naseem R, Malhi SM, Wajdi M, Jahan N et al (2021) Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance. J Oncol Pharm Pract 27(4):815–820

    CAS  PubMed  Google Scholar 

  • Allison J, Fisher J, Souter C, Bennie M (2019) What patient assessment skills are required by pharmacists prescribing systemic anti-cancer therapy? A consensus study. J Oncol Pharm Pract 25(8):1933–1944

    PubMed  Google Scholar 

  • Al-Taie A, Izzettin FV, Sancar M et al (2020) Impact of clinical pharmacy recommendations and patient counselling program among patients with diabetes and cancer in outpatient oncology setting. Eur J Cancer Care 29:e13261

    Google Scholar 

  • American College of Clinical Pharmacy (2008) The definition of clinical pharmacy. Pharmacotherapy 28(6):816–817

    Google Scholar 

  • Ashjian E, Salamin LB, Eschenburg K, Kraft S, Mackler E (2015) Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. J Am Pharm Assoc 55(5):540–545

    Google Scholar 

  • Barral M, Martin J, Carre E, Janoly-Dumenil A, Ranchon F, Parat S, Rioufol C et al (2021) 5P Study Group. How a patient personalised clinical pharmacy programme can secure therapeutic care in an orthogeriatric care pathway (5P Project). Clin Interv Aging 16:1857–1867

    CAS  PubMed  PubMed Central  Google Scholar 

  • Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198

    PubMed  PubMed Central  Google Scholar 

  • Bates JS, Auten J, Sketch MR, Patel T, Clark SM, Morgan KP et al (2019) Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation. J Oncol Pharm Pract 25(4):896–902

    PubMed  Google Scholar 

  • Baudouin A, Herledan C, Poletto N, Guillemin MD, Maison O, Garreau R et al (2021) Economic impact of clinical pharmaceutical activities in hospital wards: a systematic review. Res Social Adm Pharm 17(3):497–505

    PubMed  Google Scholar 

  • Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E et al (2016) Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer 122(4):598–610

    PubMed  Google Scholar 

  • Boşnak AS, Birand N, Diker Ö, Abdi A, Başgut B (2019) The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy. J Oncol Pharm Pract 25(6):1312–1320

    PubMed  Google Scholar 

  • Caracuel F, Baños Ú, Herrera MD, Ramírez G, Muñoz N (2014) Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm 36(2):287–290

    CAS  PubMed  Google Scholar 

  • Chan A, Shih V, Chiang J, Chew L, Tay K, Quek R et al (2013) Clinical pharmacy services and research for lymphoma patients at a cancer center. J Oncol Pharm Pract 19(1):24–30

    PubMed  Google Scholar 

  • Chew C, Chiang J, Yeoh TT (2015) Impact of outpatient interventions made at an ambulatory cancer centre oncology pharmacy in Singapore. J Oncol Pharm Pract 21(2):93–101

    PubMed  Google Scholar 

  • Collomb B, Dubromel A, Caffin AG, Herledan C, Larbre V, Baudouin A et al (2022) Assessment of patient reported outcomes (PROs) in outpatients taking oral anticancer drugs included in the real-life oncoral program. Cancers (basel) 14(3):660

    PubMed  Google Scholar 

  • Crespo A, Tyszka M (2017) Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract 23(4):243–248

    PubMed  Google Scholar 

  • da Silva BA, Krishnamurthy M (2016) The alarming reality of medication error: a patient case and review of Pennsylvania and National data. J Community Hosp Intern Med Perspect 6(4):31758

    PubMed  Google Scholar 

  • Damery S, Gratus C, Grieve R, Warmington S, Jones J, Routledge P, Greenfield S, Dowswell G, Sherriff J, Wilson S (2011) The use of herbal medicines by people with cancer: A cross-sectional survey. Br J Cancer 104:927–933

    CAS  PubMed  PubMed Central  Google Scholar 

  • Daupin J, Perrin G, Lhermitte-Pastor C, Loustalot MC, Pernot S, Savoldelli V et al (2019) Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: a cross-sectional study. J Oncol Pharm Pract 25(5):1195–1203

    CAS  PubMed  Google Scholar 

  • de Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C et al (2020) Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department. J Oncol Pharm Pract 26(5):1172–1179

    PubMed  Google Scholar 

  • Delpeuch A, Leveque D, Gourieux B, Herbrecht R (2015) Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res 35(1):457–460

    PubMed  Google Scholar 

  • Döhler N, Krolop L, Ringsdorf S, Meier K, Ko YD, Kuhn W et al (2011) Task allocation in cancer medication management - integrating the pharmacist. Patient Educ Couns 83(3):367–374

    PubMed  Google Scholar 

  • Dreischulte T, van den Bemt B, Steurbaut S (2022) European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: a position paper. Int J Clin Pharm 44(4):837–842

    PubMed  PubMed Central  Google Scholar 

  • Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J et al (2014) Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract 27(1):46–52

    PubMed  Google Scholar 

  • Edwards Z, Ziegler L, Craigs C, Blenkinsopp A, Bennett MI (2019) Pharmacist educational interventions for cancer pain management: a systematic review and meta-analysis. Int J Pharm Pract 27(4):336–345

    PubMed  Google Scholar 

  • Engdal S, Steinsbekk A, Klepp O, Nilsen OG (2008) Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 16(7):763–769

    PubMed  Google Scholar 

  • Farias TF, Aguiar KD, Rotta I, Belletti KM, Carlotto J (2016) Implementing a clinical pharmacy service in hematology. Einstein (sao Paulo) 14(3):384–390

    PubMed  Google Scholar 

  • Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A et al (2005) Medication safety in the ambulatory chemotherapy setting. Cancer 104(11):2477–2483

    PubMed  Google Scholar 

  • Gerber A, Da Silva LA, Szüts N, Simon M, Ribordy-Baudat V, Ebneter A et al (2020) Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. Health Sci Rep 3(2):e160

    PubMed  PubMed Central  Google Scholar 

  • Granados J, Salazar-Ospina A, Botero-Aguirre JP, Valencia-Quintero AF, Ortiz N, Amariles P (2020) Effect and associated factors of a clinical pharmacy model in the incidence of medication errors (EACPharModel) in the Hospital Pablo Tobón Uribe: study protocol for a stepped wedge randomized controlled trial (NCT03338725). Trials 21(1):26

    CAS  PubMed  PubMed Central  Google Scholar 

  • Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF et al (2018) PCNE definition of medication review: reaching agreement. Int J Clin Pharm 40(5):1199–1208

    PubMed  Google Scholar 

  • Guo Q, Guo H, Song J et al (2020) The role of clinical pharmacist trainees in medication reconciliation process at hospital admission. Int J Clin Pharm 42(2):796–804

    PubMed  Google Scholar 

  • Gurwitz JH, Kapoor A, Garber L et al (2021) Effect of a multifaceted clinical pharmacist intervention on medication safety after hospitalization in persons prescribed high-risk medications: a randomized clinical trial. JAMA Intern Med 181(5):610–618

    PubMed  PubMed Central  Google Scholar 

  • Hamel C, Tortolano L, Bermudez E, Desmaris R, Klein S, Slimano F et al (2018) Computerized pediatric oncology prescriptions review by pharmacist: A descriptive analysis and associated risk factors. Pediatr Blood Cancer 65(4):e26897

    Google Scholar 

  • Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA et al (2016) Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm 38(5):1124–1132

    PubMed  Google Scholar 

  • Hatoum HT, Hutchinson RA, Witte KW et al (1988) Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 22:252–259

    CAS  PubMed  Google Scholar 

  • Haukland EC, von Plessen C, Nieder C, Vonen B (2017) Adverse events in hospitalized cancer patients: a comparison to a general hospital population. Acta Oncol 56(9):1218–1223

    PubMed  Google Scholar 

  • Herledan C, Baudouin A, Larbre V, Gahbiche A, Dufay E, Alquier I et al (2020) Clinical and economic impact of medication reconciliation in cancer patients: a systematic review. Support Care Cancer 28(8):3557–3569

    PubMed  Google Scholar 

  • Hibbard JH, Stockard J, Mahoney ER, Tusler M (2004) Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 39(4 Pt 1):1005–1026

    PubMed  PubMed Central  Google Scholar 

  • Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H et al (2020) Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer 28(12):5943–5952

    PubMed  PubMed Central  Google Scholar 

  • Holle LM, Harris CS, Chan A, Fahrenbruch RJ, Labdi BA, Mohs JE et al (2017) Pharmacists’ roles in oncology pharmacy services: Results of a global survey. J Oncol Pharm Pract 23(3):185–194

    PubMed  Google Scholar 

  • Homan MJ, Reid JH, Nachar VR, Benitez LL, Brown AM, Kraft S et al (2021) Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. Support Care Cancer 29(11):6505–6510

    PubMed  Google Scholar 

  • Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther 11:187–203

    PubMed  Google Scholar 

  • Imamura M, Ogawa D, Takatori T, Yamaguchi M, Takata T, Hada T et al (2017) A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs. Biol Pharm Bull 40(11):1956–1962

    PubMed  Google Scholar 

  • Ismail M, Khan S, Khan F, Noor S, Sajid H, Yar S et al (2020) Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer 20(1):335

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jacobson JO, Polovich M, McNiff KK, Lefebvre KB, Cummings C, Galioto M et al (2009) American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 27(32):5469–5475

    PubMed  Google Scholar 

  • Jarfaut A, Nivoix Y, Vigouroux D, Kehrli P, Gaudias J, Kempf JF et al (2014) Clinical pharmacy and surgery: Review. Ann Pharm Fr 72(3):152–163

    CAS  PubMed  Google Scholar 

  • Kabel AM, Bakr MM, Alshanbari AM, Alwagdani SM, Altalhi HA, Alzaidi SH et al (2020) Perceptions and attitudes towards clinical pharmacy services and their impact on the management of cancer in Taif, Saudi Arabia. Asian Pac J Cancer Prev 21(2):531–538

    PubMed  PubMed Central  Google Scholar 

  • Kaya M, Nakamura K, Nagamine M, Suyama Y, Nakajo M, Uchida R et al (2021) A retrospective study comparing interventions by oncology and non-oncology pharmacists in outpatient chemotherapy. Cancer Rep 4(4):e1371

    Google Scholar 

  • Knez L, Laaksonen R, Duggan C (2010) Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol 44(4):249–256

    PubMed  PubMed Central  Google Scholar 

  • Korayem GB, Badreldin HA, Eljaaly K, Aldemerdash A, Al-Suhaibani LK, Joharji H et al (2021) Clinical pharmacy definition, required education, training and practice in Saudi Arabia: A position statement by the Saudi society of clinical pharmacy. Saudi Pharm J 29(11):1343–1347

    PubMed  PubMed Central  Google Scholar 

  • Kucuk E, Bayraktar-Ekincioglu A, Erman M, Kilickap S (2020) Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. J Oncol Pharm Pract 26(3):595–602

    PubMed  Google Scholar 

  • Lau KM, Saunders IM, Sacco AG, Barnachea LC (2020) Evaluation of pharmacist interventions in a head and neck medical oncology clinic. J Oncol Pharm Pract 26(6):1390–1396

    PubMed  Google Scholar 

  • Laurent V, Saillard J, Thierry M, Lepelletier A, Fronteau C, Huon JF (2021) Anticancer agents and herbal medicine: Interactions that are often unrecognized. J Oncol Pharm Pract 27(2):322–328

    PubMed  Google Scholar 

  • Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D et al (2015) Study impacto: Descriptive analyzis of pharmacist’s clinical practice in onco-hematology. Ann Pharm Fr 73(3):223–228

    PubMed  Google Scholar 

  • Le S, Chang B, Pham A, Chan A (2021) Impact of pharmacist-managed immune checkpoint inhibitor toxicities. J Oncol Pharm Pract 27(3):596–600

    CAS  PubMed  Google Scholar 

  • Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R et al (2021) Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer 127(11):1827–1835

    CAS  PubMed  Google Scholar 

  • Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W et al (2012) Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 20(11):2669–2677

    PubMed  PubMed Central  Google Scholar 

  • Lihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi Y et al (2012) Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract 18(4):753–760

    Google Scholar 

  • Lipitz-Snyderman A, Pfister D, Classen D, Atoria CL, Killen A, Epstein AS et al (2017) Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer 123(23):4728–4736

    PubMed  Google Scholar 

  • Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus FV (2014) Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm 36(6):1251–1259

    PubMed  Google Scholar 

  • Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S (2019) A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. J Oncol Pharm Pract 25(1):130–139

    PubMed  Google Scholar 

  • Martínez-Bautista MJ, Mangues-Bafalluy I, Cajaraville-Ordoñana G, Carreras-Soler MJ, Clopés-Estela A, Moreno-Martínez E (2019) Survey of oncohematological pharmaceutical care situation in Spain. Farma Hosp 43(6):194–201

    Google Scholar 

  • McKee M, Frei BL, Garcia A, Fike D, Soefje SA (2011) Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract 17(4):387–394

    PubMed  Google Scholar 

  • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097

    PubMed  PubMed Central  Google Scholar 

  • Morimoto Y, Takei H, Tachibana K, Nakazato Y, Tanaka R, Nagashima Y et al (2018) Role of pharmacists in completion of adjuvant cisplatin-vinorelbine chemotherapy in japanese patients with non-small cell lung cancer. Yakugaku Zasshi 138(3):437–442

    CAS  PubMed  Google Scholar 

  • Moukafih B, Abahssain H, Mrabti H, Errihani H, Rahali Y, Taoufik J et al (2021) Impact of clinical pharmacy services in a hematology/oncology ward in Morocco. J Oncol Pharm Pract 27(2):305–311

    PubMed  Google Scholar 

  • Muñoz-Pichuante D, Villa-Zapata L (2020) Benefit of incorporating clinical pharmacists in an adult intensive care unit: a cost-saving study. J Clin Pharm Ther 45:1127–1133

    PubMed  Google Scholar 

  • Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS et al (2013) Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs. J Oncol Pharm Pract 19(1):8–17

    CAS  PubMed  Google Scholar 

  • Oliveira CS, Silva MP, Miranda ÍK, Calumby RT, de Araújo-Calumby RF (2021) Impact of clinical pharmacy in oncology and hematology centers: a systematic review. J Oncol Pharm Pract 27(3):679–692

    PubMed  Google Scholar 

  • Omar NE, Elazzazy S, Abdallah O, Nashwan AJ, Eltorki Y, Afifi HM et al (2020) Perceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in Qatar. J Oncol Pharm Pract 26(5):1086–1096

    PubMed  Google Scholar 

  • Opsomer MA, Anota A, Noblot-Rossignol M, Bonnetain F, Pernot C, Chretien ML et al (2016) Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies. Ann Pharm Fr 74(6):439–447

    CAS  PubMed  Google Scholar 

  • Overhage JM, Lukes A (1999) Practical, reliable, comprehensive method for characterizing pharmacists’ clinical activities. Am J Health Syst Pharm 56(23):2444–2450

    CAS  PubMed  Google Scholar 

  • Penm J, Vaillancourt R, Pouliot A (2019) Defining and identifying concepts of medication reconciliation: an international pharmacy perspective. Res Social Adm Pharm 15(6):632–640

    PubMed  Google Scholar 

  • Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C (2017) Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract 13(7):e613–e622

    PubMed  Google Scholar 

  • Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S et al (2011) Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer 11:478

    PubMed  PubMed Central  Google Scholar 

  • Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N et al (2012) Predictors of prescription errors involving anticancer chemotherapy agents. Eur J Cancer 48(8):1192–1199

    PubMed  Google Scholar 

  • Renna CE, Dow EN, Bergsbaken JJ, Leal TA (2019) Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities. J Oncol Pharm Pract 25(4):954–960

    PubMed  Google Scholar 

  • Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99(8):592–600

    PubMed  Google Scholar 

  • Ruder AD, Smith DL, Madsen MT, Kass FH 3rd (2011) Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic? J Oncol Pharm Pract 17(4):425–432

    PubMed  Google Scholar 

  • Sam S, Guérin A, Rieutord A, Belaiche S, Bussières JF (2018) Roles and impacts of the transplant pharmacist: a systematic review. Can J Hosp Pharm 71(5):324–337

    PubMed  PubMed Central  Google Scholar 

  • Schindel TJ, Given LM (2013) The pharmacist as prescriber: a discourse analysis of newspaper media in Canada. Res Social Adm Pharm 9(4):384–395

    PubMed  Google Scholar 

  • Segal EM, Bates J, Fleszar SL, Holle LM, Kennerly-Shah J, Rockey M et al (2019) Demonstrating the value of the oncology pharmacist within the healthcare team. J Oncol Pharm Pract 25(8):1945–1967

    PubMed  Google Scholar 

  • Shah S, Dowell J, Greene S (2006) Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 40(9):1527–1533

    PubMed  Google Scholar 

  • Shrestha S, Shakya D, Palaian S (2020) Clinical pharmacy education and practice in nepal: a glimpse into present challenges and potential solutions. Adv Med Educ Pract 11:541–548

    PubMed  PubMed Central  Google Scholar 

  • Société Française de Pharmacie Clinique. Lexique de Pharmacie Clinique. [Online]. 2018 [consulted 20/12/2021]. Available on: https://sfpc.eu/wp-content/uploads/2019/11/1-s.0.S2211104218302005-mmc1.pdf

  • Son H, Kim J, Kim C, Ju J, Lee Y, Rhie SJ (2018) Pharmacist-led interdisciplinary medication reconciliation using comprehensive medication review in gynaecological oncology patients: a prospective study. Eur J Hosp Pharm 25(1):21–25

    PubMed  Google Scholar 

  • Stämpfli D, Baumgartner P, Boeni F et al (2019) Translation and validation of a tool to assess the impact of clinical pharmacists’ interventions. Int J Clin Pharm 41:56–64

    PubMed  Google Scholar 

  • Suzuki H, Suzuki S, Kamata H, Sugama Y, Demachi K, Ikegawa K et al (2019) Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J Oncol Pharm Pract 25(7):1558–1563

    CAS  PubMed  Google Scholar 

  • Tariq RA, Vashisht R, Sinha A, Scherbak Y (2021) StatPearls [Internet] Treasure Island, FL: StatPearls Publishing. Medication dispensing errors and prevention

  • Tefera GM, Zeleke AZ, Jima YM, Kebede TM (2020) Drug therapy-related problems and the role of clinical pharmacist in surgery Ward: prospective observational and interventional study. Drug Healthc Patient Saf 12:71–83

    PubMed  PubMed Central  Google Scholar 

  • Tezcan S, İzzettin FV, Sancar M, Turhal NS, Yumuk PF (2018) Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer. Eur J Hosp Pharm 25(e1):e17–e20

    PubMed  Google Scholar 

  • Theuser AK, Hack CC, Fasching PA, Antoniadis S, Grasruck K, Wasner S et al (2021) Patterns and trends of herbal medicine use among patients with gynecologic cancer. Geburtshilfe Frauenheilkd 81(6):699–707

    PubMed  PubMed Central  Google Scholar 

  • Tissot M, Valnet-Rabier M, Stalder T, Limat S, Davani S, Nerich V (2021) Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies 77:291

    Google Scholar 

  • Van der Linden L, Hias J, Walgraeve K, Flamaing J, Tournoy J, Spriet I (2020) Clinical pharmacy services in older inpatients: an evidence-based review. Drugs Aging 37(3):161–174

    PubMed  Google Scholar 

  • van Leeuwen RW, Swart EL, Boven E et al (2011) Potential drug interactions in cancer therapy: A prevalence study using an advanced screening method. Ann Oncol 22:2334–2341

    PubMed  Google Scholar 

  • van Leeuwen RWF, Jansman FGA, van den Bemt P, de Man F, Piran F, Vincenten I et al (2015) Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 26(5):992–997

    PubMed  Google Scholar 

  • van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA (2004) Drug-related problem classification systems. Ann Pharmacother 38:859–867

    PubMed  Google Scholar 

  • Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG et al (2015) EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther 40(2):196–203

    CAS  PubMed  Google Scholar 

  • Vega TG, Sierra-Sánchez JF, Martínez-Bautista MJ, García-Martín F, Suárez-Carrascosa F, Baena-Cañada JM (2016) Medication reconciliation in oncological patients: a randomized clinical trial. J Manag Care Spec Pharm 22(6):734–740

    PubMed  Google Scholar 

  • Vucur C, Wirtz DA, Weinhold L, Zipfel M, Schmid M, Schmidt-Wolf IG et al (2021) Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles. J Oncol Pharm Pract 27(6):1439–1446

    CAS  PubMed  Google Scholar 

  • Walsh KE, Dodd KS, Seetharaman K, Roblin DW, Herrinton LJ, Von Worley A et al (2009) Medication errors among adults and children with cancer in the outpatient setting. J Clin Oncol 27(6):891–896

    PubMed  Google Scholar 

  • Wang Y, Wu H, Xu F (2015) Impact of clinical pharmacy services on KAP and QOL in cancer patients: a single-center experience. Biomed Res Int 2015:502431

    PubMed  PubMed Central  Google Scholar 

  • Weingart SN, Zhang L, Sweeney M, Hassett M (2018) Chemotherapy medication errors. Lancet Oncol 19(4):e191–e199

    PubMed  Google Scholar 

  • Xie C, Mu X, Hu Z, Wang W, Huang W, Huang G et al (2020) Impact of pharmaceutical care in the orthopaedic department. J Clin Pharm Ther 45(3):401–407

    PubMed  Google Scholar 

  • Xu P, Hu YY, Yuan HY, Xiang DX, Zhou YG, Cave AJ, Banh HL (2019) the impact of a training program on clinical pharmacists on pharmacy clinical services in a tertiary hospital in Hunan China. J Multidiscip Healthc 12:975–980

    PubMed  PubMed Central  Google Scholar 

  • Zecchini C, Vo TH, Chanoine S, Lepelley M, Laramas M, Lemoigne A, Allenet B, Federspiel I, Bedouch P (2020) BMC Health Serv Res 20(1):113

    PubMed  PubMed Central  Google Scholar 

  • Zhou M, Desborough J, Parkinson A, Douglas K, McDonald D, Boom K (2019) Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences. Int J Pharm Pract 27(6):479–489

    PubMed  Google Scholar 

Download references

Funding

There were no sources of funding associated with this manuscript.

Author information

Author notes

  1. Claire Lattard, Amandine Baudouin, Florence Ranchon and Catherine Rioufol equally contributed.

Authors and Affiliations

  1. Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, Pierre-Bénite, France

    Claire Lattard, Amandine Baudouin, Virginie Larbre, Chloé Herledan, Ariane Cerutti, Marie-Anne Cerfon, Reine Kimbidima, Anne-Gaelle Caffin, Nicolas Vantard, Vérane Schwiertz, Florence Ranchon & Catherine Rioufol

  2. Université Lyon 1- EA 3738, CICLY Centre Pour l’Innovation en Cancérologie de Lyon, 69921, Lyon, Oullins Cedex, France

    Virginie Larbre, Chloé Herledan, Florence Ranchon & Catherine Rioufol

Authors
  1. Claire Lattard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amandine Baudouin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Virginie Larbre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chloé Herledan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ariane Cerutti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marie-Anne Cerfon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Reine Kimbidima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anne-Gaelle Caffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nicolas Vantard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vérane Schwiertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Florence Ranchon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Catherine Rioufol
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C.L. and A.B. wrote the main manuscript text. All authors reviewed the manuscript.

Corresponding author

Correspondence to Catherine Rioufol.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lattard, C., Baudouin, A., Larbre, V. et al. Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review. J Cancer Res Clin Oncol 149, 7905–7924 (2023). https://doi.org/10.1007/s00432-023-04630-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-04630-4

Keywords

Search

Navigation